\n\n\n\n
Why This Guideline Matters<\/h3>\n\n\n\n
This milestone, highlighted in the Alzheimer\u2019s Association blood test guideline<\/strong>, shifts the field of neurology<\/strong> toward less invasive and more affordable options. For patients and caregivers searching for a blood test for Alzheimer\u2019s accuracy<\/strong>, wanting to understand the p-tau217 blood test meaning<\/strong>, or considering APOE testing for Alzheimer\u2019s<\/strong>, these innovations provide clear answers. They also respond to common questions like \u201chow to diagnose Alzheimer\u2019s without spinal tap\u201d<\/strong> and whether blood tests vs PET for Alzheimer\u2019s<\/strong> are the better option.<\/p>\n\n\n\n On May 16, 2025<\/strong>, the FDA cleared<\/strong> the first Alzheimer\u2019s blood test<\/strong>\u2014a plasma assay reporting the p-tau217\/\u03b2-amyloid 1-42 ratio<\/strong>. While not a general population screening tool, it represents a meaningful step forward in delivering a less invasive Alzheimer\u2019s diagnosis<\/strong>.<\/p>\n\n\n\n As Heather Snyder, PhD<\/strong>, of the Alzheimer\u2019s Association explained, this development marks a new era in Alzheimer\u2019s diagnostics<\/strong>, improving access and reducing reliance on PET scans and spinal taps. With providers like Ulta Lab Tests<\/strong> offering affordable Alzheimer\u2019s testing online<\/strong>, patients and families can now search for an Alzheimer\u2019s blood test near me<\/strong>, order from the best labs for cognitive decline<\/strong>, and use rule-out labs for memory loss<\/strong> to take action sooner and protect long-term brain health & prevention<\/strong>.<\/p>\n\n\n\n If you or a loved one has new or worsening cognitive concerns, talk with your clinician about evaluation and Alzheimer\u2019s blood tests<\/strong>:<\/p>\n\n\n\n Important:<\/strong> Many reversible<\/strong> issues can mimic dementia\u2014thyroid disorders, vitamin B12<\/strong> or folate<\/strong> deficiency, depression, sleep apnea, medication effects, infection. Including rule\u2011out labs for memory loss<\/strong> is essential in any thorough workup (see below).<\/p>\n\n\n\n Traditional diagnosis has relied on clinical testing plus amyloid or tau PET scans<\/strong> or CSF<\/strong> analysis. While effective, those methods are invasive, expensive, and not always available<\/strong>. Blood\u2011based biomarkers offer a practical first step that can:<\/p>\n\n\n\n Core Alzheimer\u2019s biomarkers (blood\u2011based):<\/strong><\/p>\n\n\n\n Supportive biomarkers of neurodegeneration and astroglial injury:<\/strong><\/p>\n\n\n\n Kidney function matters:<\/strong> Emerging evidence shows reduced eGFR\/CKD can elevate plasma p\u2011tau217<\/strong>values. Some algorithms use ratios<\/strong> that are less affected. Clinicians may review renal function<\/strong> alongside results. <\/p>\n<\/blockquote>\n\n\n\n Results should be interpreted by a qualified clinician. Blood tests aid<\/strong> diagnosis; they do not replace clinical evaluation.<\/p>\n<\/blockquote>\n\n\n\n
\n\n\n\nFDA Clearance: A Breakthrough Step<\/h3>\n\n\n\n
\n\n\n\nA New Era in Alzheimer\u2019s Diagnostics<\/h3>\n\n\n\n
![\"Clinician](\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2025\/08\/Alzheimers-Blood-Test-Consultation-p-tau217-and-A%CE%B24240-Results-Explained.jpeg?resize=1024%2C1024&quality=100&ssl=1\")
\n\n\n\nA Major Milestone in Alzheimer\u2019s Diagnosis<\/h2>\n\n\n\n
\n
\n\n\n\nSigns & Symptoms: When to Consider Testing<\/h2>\n\n\n\n
\n
\n\n\n\nWhy Blood\u2011Based Testing Is Transformative<\/h2>\n\n\n\n
\n
\n\n\n\nWhat These Alzheimer\u2019s Blood Tests Measure<\/h2>\n\n\n\n
\n
\n
\n
\n\n\n\nHow Lab Tests Help Diagnose and Manage Alzheimer\u2019s<\/h2>\n\n\n\n
\n
Combining p\u2011tau217<\/strong> with A\u03b242\/40<\/strong> improves agreement with PET\/CSF and helps determine who needs confirmatory testing<\/strong>\u2014especially in specialty settings.<\/li>\n\n\n\n
Some disease\u2011modifying therapies (e.g., anti\u2011amyloid monoclonal antibodies<\/strong>) require evidence of amyloid pathology. Blood\u2011based biomarkers<\/strong> can be a first step<\/strong> to confirm eligibility and plan ARIA\u2011risk<\/strong> counseling (often informed by APOE<\/strong> status).<\/li>\n\n\n\n
Additional labs\u2014thyroid (TSH)<\/strong>, B12\/folate<\/strong>, vitamin D<\/strong>, lipids<\/strong>, A1c<\/strong>, inflammation markers<\/strong>\u2014help detect treatable contributors<\/strong> to cognitive decline.<\/li>\n<\/ol>\n\n\n\n
\n\n\n\nThe Alzheimer\u2019s Association\u2019s Updated Recommendations (Plain\u2011Language Summary)<\/h2>\n\n\n\n
\n
\n\n\n\nIndividual Test Breakdowns (with direct ordering links)<\/h2>\n\n\n\n
\n
p\u2011tau217 (Plasma)<\/h3>\n\n\n\n
\n
Amyloid Beta 42\/40 Ratio (Plasma)<\/h3>\n\n\n\n
\n
p\u2011tau181 (Plasma)<\/h3>\n\n\n\n
\n
APOE Testing (Isoform \/ Genotype)<\/h3>\n\n\n\n
\n
Cardio IQ\u2122 APOE Genotype<\/strong>
ADmark\u00ae APOE Genotype Analysis<\/strong><\/li>\n<\/ul>\n\n\n\nNfL and GFAP (Supportive Markers)<\/h3>\n\n\n\n
\n
\n\n\n\nWhat to Expect From Your Results<\/h2>\n\n\n\n
\n
\n\n\n\nBlood Tests vs PET or Spinal Tap: How They Fit Together<\/h2>\n\n\n\n
\n